Amylx Pharmaceuticals Inc vs SpaceX — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while SpaceX trades at $146.22 (market cap $1.76T). The key difference: SpaceX is far larger — about 666.7× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, SpaceX nearer its low. Which is the better fit depends on your goals.
| AMLX | SPCX | |
|---|---|---|
Market Cap | $2.64B | $1.76T |
Sector | Health | Technology |
52-Week High | $24.19 | $202.09 |
52-Week Low | $7.82 | $108.27 |
Enterprise Value | $2.39B | $1.70T |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
SPCX stock trades at $146.22, up 5.39% today, buoyed by strong technical momentum and positive news flow. The stock shows bullish moving average signals and trades above key support levels. Recent Q2 earnings beat expectations, though the company remains unprofitable with a net income margin of -35.66%. High-profile institutional investments, including Norway's sovereign wealth fund, underscore growing confidence in SpaceX's AI and Starlink growth trajectory.
Outlook is optimistic given analyst consensus and AI-driven revenue potential, but risks include persistent losses, high valuation multiples, and insider share unlocks. The consensus price target of $228.52 implies significant upside if execution aligns with ambitious growth plans.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →